As of May 30, 2026, Crinetics Pharmaceuticals's top three insider holders are Richard Scott Struthers (President Ceo, 661.21K shares), Richard Scott Struthers (President Ceo, 404.78K shares), Richard Scott Struthers (President Ceo, 270.00K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Camille L Bedrosian | - | 16,300 | 0 | 13 Jun, 2025 |
| Matthew K Fust | - | 22,836 | 0 | 30 Sep, 2025 |
| Alan Seth Krasner | Chief Medical Officer | 43,210 | 0 | 19 Oct, 2023 |
| Coelho Rogerio Vivaldi | - | 16,300 | 0 | 13 Mar, 2026 |
| Tobin Schilke | Chief Financial Officer | 78,121 | 0 | 04 Mar, 2026 |
| Marc Wilson | Cfo | 111,092 | 0 | 30 Sep, 2024 |
| Richard Scott Struthers | President Ceo | 0 | 661,205 | 16 May, 2025 |
| Weston Nichols | - | 16,300 | 0 | 13 Jun, 2025 |
| James Hassard | Chief Commercial Officer | 29,259 | 0 | 09 Jul, 2024 |
| Ajay Madan | Chief Development Officer | 176,995 | 0 | 02 Mar, 2022 |
| Caren Deardorf | - | 16,300 | 0 | 13 Jun, 2025 |
| Jeff E. Knight | Chief Dev. Operating Officer | 105,289 | 0 | 10 Apr, 2026 |
| Stephen F. Betz | Chief Scientific Officer | 137,101 | 0 | 18 Mar, 2026 |
| Dana Pizzuti | Chief Med And Dev Officer | 66,837 | 0 | 03 Dec, 2025 |
| Isabel Kalofonos | Chief Commercial Officer | 34,834 | 0 | 25 Feb, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 08 Apr, 2026 | Jeff E. Knight | Common Stock | A | 49,474 | $23.98 | 161,492 | D | M |
| 08 Apr, 2026 | Jeff E. Knight | Common Stock | A | 49,474 | $23.98 | 161,492 | D | M |
| 08 Apr, 2026 | Jeff E. Knight | Common Stock | A | 9,624 | $20.02 | 171,116 | D | M |
| 08 Apr, 2026 | Jeff E. Knight | Common Stock | A | 9,624 | $20.02 | 171,116 | D | M |
| 08 Apr, 2026 | Jeff E. Knight | Common Stock | A | 19,336 | $19.64 | 190,452 | D | M |
| 08 Apr, 2026 | Jeff E. Knight | Common Stock | A | 19,336 | $19.64 | 190,452 | D | M |
| 08 Apr, 2026 | Jeff E. Knight | Common Stock | D | 85,163 | $40.10 | 105,289 | D | S |
| 08 Apr, 2026 | Jeff E. Knight | Common Stock | D | 85,163 | $40.10 | 105,289 | D | S |
| 08 Apr, 2026 | Jeff E. Knight | Stock Option (Right to Buy) | D | 49,474 | $0.00 | 63,027 | D | M |
| 08 Apr, 2026 | Jeff E. Knight | Stock Option (Right to Buy) | D | 49,474 | $0.00 | 63,027 | D | M |
| 08 Apr, 2026 | Jeff E. Knight | Stock Option (Right to Buy) | D | 9,624 | $0.00 | 10,589 | D | M |
| 08 Apr, 2026 | Jeff E. Knight | Stock Option (Right to Buy) | D | 9,624 | $0.00 | 10,589 | D | M |
| 08 Apr, 2026 | Jeff E. Knight | Stock Option (Right to Buy) | D | 19,336 | $0.00 | 65,977 | D | M |
| 08 Apr, 2026 | Jeff E. Knight | Stock Option (Right to Buy) | D | 19,336 | $0.00 | 65,977 | D | M |
| 16 Mar, 2026 | Richard Scott Struthers | Common Stock | D | 13,196 | $37.11 | 413,563 | D | S |
| 16 Mar, 2026 | Jeff E. Knight | Common Stock | D | 5,950 | $37.11 | 115,979 | D | S |
| 16 Mar, 2026 | Jeff E. Knight | Common Stock | D | 5,950 | $37.11 | 115,979 | D | S |
| 16 Mar, 2026 | Jeff E. Knight | Common Stock | D | 5,950 | $37.11 | 115,979 | D | S |
| 16 Mar, 2026 | Richard Scott Struthers | Common Stock | D | 13,196 | $37.11 | 413,563 | D | S |
| 16 Mar, 2026 | Stephen F. Betz | Common Stock | D | 6,371 | $37.11 | 141,342 | D | S |